Licenses Clear Path For Daclatasvir In Asia/Africa HCV/HIV Program
This article was originally published in PharmAsia News
The first supplies of daclatasvir for use in a new US-coordinated program aimed at improving drug access for patients co-infected with HIV/HCV in Asian and African countries will reach first recipients shortly.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.